HK1219231A1 - 治疗儿童实体瘤的方法 - Google Patents

治疗儿童实体瘤的方法 Download PDF

Info

Publication number
HK1219231A1
HK1219231A1 HK16107309.3A HK16107309A HK1219231A1 HK 1219231 A1 HK1219231 A1 HK 1219231A1 HK 16107309 A HK16107309 A HK 16107309A HK 1219231 A1 HK1219231 A1 HK 1219231A1
Authority
HK
Hong Kong
Prior art keywords
solid tumor
methods
treatment
pediatric solid
pediatric
Prior art date
Application number
HK16107309.3A
Other languages
English (en)
Chinese (zh)
Inventor
．貝妮特愛波
B．贝妮特爱波
．埃利亞斯
I．埃利亚斯
．雷恩施樂
M．雷恩施乐
．德賽
N．P．德赛
Original Assignee
阿布拉科斯生物科学有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿布拉科斯生物科学有限公司 filed Critical 阿布拉科斯生物科学有限公司
Publication of HK1219231A1 publication Critical patent/HK1219231A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
HK16107309.3A 2013-03-13 2014-03-10 治疗儿童实体瘤的方法 HK1219231A1 (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US61/780,658 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US61/805,817 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US61/829,940 2013-05-31
US201361909868P 2013-11-27 2013-11-27
US61/909,868 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Publications (1)

Publication Number Publication Date
HK1219231A1 true HK1219231A1 (zh) 2017-03-31

Family

ID=51537501

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107309.3A HK1219231A1 (zh) 2013-03-13 2014-03-10 治疗儿童实体瘤的方法

Country Status (12)

Country Link
US (1) US20160015817A1 (https=)
EP (1) EP2968253A4 (https=)
JP (3) JP6387389B2 (https=)
KR (1) KR20150126671A (https=)
CN (1) CN105209035A (https=)
AU (2) AU2014228386B2 (https=)
CA (1) CA2903470A1 (https=)
HK (1) HK1219231A1 (https=)
IL (1) IL240987A0 (https=)
MX (1) MX2015011783A (https=)
NZ (1) NZ630367A (https=)
WO (1) WO2014143613A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
JP6216721B2 (ja) 2011-12-14 2017-10-18 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3998069T3 (pl) 2015-06-29 2025-03-31 Abraxis Bioscience, Llc Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
JP7832108B2 (ja) 2019-10-28 2026-03-17 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
CN105209035A (zh) 2015-12-30
JP2018062528A (ja) 2018-04-19
CA2903470A1 (en) 2014-09-18
JP2019163334A (ja) 2019-09-26
EP2968253A4 (en) 2016-11-02
KR20150126671A (ko) 2015-11-12
IL240987A0 (en) 2015-11-30
AU2014228386A1 (en) 2015-09-24
NZ630367A (en) 2017-02-24
WO2014143613A1 (en) 2014-09-18
MX2015011783A (es) 2015-12-01
JP6387389B2 (ja) 2018-09-05
US20160015817A1 (en) 2016-01-21
JP2016512513A (ja) 2016-04-28
AU2014228386B2 (en) 2018-11-29
EP2968253A1 (en) 2016-01-20
AU2019201357A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
HK1219231A1 (zh) 治疗儿童实体瘤的方法
HK1220405A1 (zh) 治疗膀胱癌的方法
IL273090B (en) Methods and preparations for the treatment of cancer
PH12016502066A1 (en) Methods of treating bladder cancer
IL239981A0 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
HK1218506A1 (zh) 治療黑素瘤的方法
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
MX2016007885A (es) Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EP3256110A4 (en) Compositions and methods of tumor treatment utilizing nanoparticles
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
HK1216083A1 (zh) 经动脉的药物递送
HK1220155A1 (zh) 治疗癌症的方法
EP3004396A4 (en) Methods and compositions for the treatment of cancer
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3188800A4 (en) Compositions and methods for treating fibrosing disorders and cancer
EP3044590A4 (en) Methods and compositions for tumor vasculature imaging and targeted therapy
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
AU2014902024A0 (en) Nanoparticle compositions for the treatment of cancer